At the 2019 ATS conference in Dallas, TX, USA, Frank Sciurba (University of Pittsburgh Medical Centre, Pittsburgh, PA, USA) discusses the challenges faced by patients with heterogeneous emphysema with negative collateral ventilation (CV) status and the potential of the Zephyr Valve to improve lung function, exercise tolerance and quality of life.
Questions
1. What challenges do patients with heterogeneous emphysema with negative collateral ventilation (CV) status currently face? (0:04)
2. Please briefly outline how the Zephyr Valve works in patients with heterogeneous emphysema with negative CV. (0:45)
3. What is the relationship between reductions in global hyperinflation and clinical outcomes such as lung function, exercise tolerance and quality of life, and how does the Zephyr Valve affect these? (1:43)
4. How long does it take for improvements with the Zephyr Valve? (2:45)
5. What unmet needs remain for patients with emphysema? (3:45)
Speaker’s Disclosures: Frank Sciurba has received institutional research funds from Pulmonx.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at ATS 2019, Dallas, TX, USA, May 2019.
